TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06576752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital follow-up and uptitration of medications at home after hospital discharge for heart failure
Description: Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up and uptitration of medications at the hospital outpatient-clinic after hospital discharge for heart failure
Description: Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
Study: NCT05461248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stoma drainage reinfusion
Description: 1 month after radical rectal surgery, the stoma drainage fluid was reinfused once a week for 2 months. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard of Care - No Return of Stoma Drain
Description: No Return of Stoma Drain
Study: NCT06446193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NDTx-01
Description: NDTx-01 intervention: Run 'NDTx-01' application on a smartphone 5 times a week, for 6 weeks, 30 sessions in total.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAU
Description: TAU: Autism Spectrum Disorders(ASD) or Social Communication Disorders(SCD)-related treatment/rehabilitation/education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: TAU: Autism Spectrum Disorders(ASD) or Social Communication Disorders(SCD)-related treatment/rehabilitation/education
Study: NCT06651372

Intervention type: BIOLOGICAL
Intervention: The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons
Description: Serological tests detecting IgM and IgG
Study: NCT06650072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified coronally advanced tunnel technique combined with multiple palatal micro connective tissue grafts
Description: The connective tissue graft will be harvested from the palate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified coronally advanced tunnel technique combined with multiple tuberosity micro connective tissue grafts
Description: The connective tissue graft will be harvested from the maxillary tuberosity.
Study: NCT06650683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pediatric HAH
Description: Pediatric HAH nursing support for home nursery care provided by parents as part of their child's disease.
Study: NCT05780515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANX009
Description: ANX009 will be administered per schedule specified in the arm description.
Study: NCT05248425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Monitoring
Description: Questionnaire responses that indicate new or worsening symptoms will be monitored by a study nurse who will contact the participant for clinical assessment and develop a management plan following irAEs management guidelines.
Study: NCT05807542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.
Study: NCT06301542

Intervention type: DEVICE
Intervention: Functional electrical stimulation
Description: The FES system will be placed on the plantar flexors, dorsiflexion, and quadriceps muscles and be paired with the machine learning directed inertial measurement units.

Intervention type: DEVICE
Intervention: Functional electrical stimulation
Description: The FES system will be placed on the plantar flexors, dorsiflexion, and quadriceps muscles and be paired with the machine learning directed inertial measurement units.
Study: NCT05454319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Home-based biofeedback with medical device
Study: NCT06469554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEP-only group
Description: Participants in this group will receive a Multicomponent Exercise Program (MEP) consisting of: Supervised aerobic training on a stationary bike Progressive resistance/strength training using weight machines Balance training exercises The MEP sessions will be 30-40 minutes long and conducted over 4 consecutive days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEP-VR group
Description: Participants in this group will receive the same MEP intervention as the MEP-only group.~Additionally, they will use an immersive virtual reality (IVR) system during the exercise program
Study: NCT06525350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glumetinib tablets
Description: An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
Study: NCT05024812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib＋toripalimab + SOX
Description: phase Ib: fruquintinib (dose finding): L1: 3 mg/d，L2: 4 mg/d，L3: 5 mg/d, qd po, D1-14, Q3W toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W. phase II: fruquintinib: RP2D toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W.
Study: NCT06222996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vaccine hesitation training
Description: Training will be given to primiparous expectant mothers on vaccine hesitation with the support of the web page created by the researcher
Study: NCT05887518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Socks Developed with Wearable Technology
Description: This new material will have the ability to prevent hypothermia by rewarming the patient when the body temperature drops below 360C and will reduce the risk of DVT that may develop in patients due to hypothermia. Thus, a single material will be used for two important complications of the surgical process, such as hypothermia and DVT, which negatively affect patient outcomes. This situation suggests that this material developed with an innovative approach will be more cost effective.
Study: NCT05927207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRIP
Description: TRIP is a mobile app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD), comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
Study: NCT06061848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SLIT Grazax ALK Nordic 75 000 SQ-T
Description: Daily sublingual grass allergen tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ILIT + Vitamin D
Description: 1 mL of Vicotrat D3, Heyl Pharma, 100 000 IU/mL, as intramuscular injection. Followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ILIT + placebo
Description: 1 ml of Sodium chloride solution 9 mg/mL as intramuscular injection followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
Study: NCT05847569

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Belantamab Mafodotin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT05790343

Intervention type: BEHAVIORAL
Intervention: BAPHYC
Description: Nine weekly peer led group meetings
Study: NCT06440525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSLV-132
Description: Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride solution
Study: NCT06657274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RICORDO-DTx
Description: Tele@cognitive treatment group will receive a total of 5 weeks (3 sessions/week, 45 minutes/session) of home-based cognitive rehabilitation activities with an innovative digital solution for remote rehabilitation of cognitive difficulties according to digital therapeutics delivery model. Subjects assigned to the tele@cognitive group can access the app RICORDO-DTx through a tablet showing the prescribed rehabilitation activities to be performed.~Each cognitive exercise is structured into five levels of difficulty that adaptively increase (algorithm on both subject's performance and perceived difficulty). All data about patient progress and adherence will be collected with this digital solution and will be available to evaluate and monitor the results of rehabilitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based unstructured cognitive stimulation
Description: Subjects assigned to the home-based unstructured cognitive stimulation will be requested to work on detailed activities for the same duration of the tele@cognitive intervention (3 sessions/week, 45 minutes/session). They will receive, from the therapist, an instructions booklet and a participant diary.
Study: NCT05638360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ru Yi Jin Huang Powder
Description: Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patch contains 13g starch and 10c.c. water.
Study: NCT06657547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal conditions
Description: Participants are administered salmeterol, after which they perform various performance tests in normal conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
Study: NCT05847569

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study: NCT05390853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Active stimulation is carried out with a current intensity of 2 milliAmpere. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Sham stimulation is carried out through a dedicated program, which increases the current for several seconds up to the target intensity and then decreases it gradually in a few seconds, so that subjects experience the same itching and tingling experience as in active stimulation, but they do not receive any significant therapeutic currents.~Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice.
Study: NCT04969263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (Pfizer/BioNTech)
Description: 30 microgram dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (Moderna)
Description: 100 microgram dose
Study: NCT06650800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Single-dose psilocybin administration: oral ingestion of one 25 mg capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: 1.5 hour brain MRI before and after psilocybin administration
Study: NCT04677907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis
Description: Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona (Zimmer) posterior stabilised cemented Trabecular Metal™ (Tibia and Femur) prosthesis
Description: Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
Study: NCT06540833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284
Description: ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
Study: NCT06525350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glumetinib tablets
Description: An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB1801 (docetaxel, albumin-bound）
Description: An improved new formulations of docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: A chemotherapy drug
Study: NCT06570694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OverThinking
Description: OverThinking is a mobile application ecological momentary intervention for iOS and Android, which has been designed for the reduction of experiential avoidance in rumination. The application primarily consists of psychoeducation content and related exercises intended to be delivered over a four-week period. In order to examine the effectiveness of the application during the course of the intervention and to examine user-experiences of using the application for the purpose of rumination intervention, a number of self-report tools are embedded.
Study: NCT06657547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heated conditions
Description: Participants are administered salmeterol, after which they perform various performance tests in heated conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.

Intervention type: DRUG
Group type: OTHER
Intervention: Salmeterol inhalation and urine samples
Description: After the experimental day under normal conditions, all participants are administered 200 µg of salmeterol daily (8 puffs from the MDI device) during a 6-day intervention period. Two hours after inhalation, the participants collect spot urine samples at home
Study: NCT06663137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Description: NDV01 is administered intravesically using a catheter.
Study: NCT06664437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Description: Patients were in supine lying position during the whole treatment. The techniques were performed in a rhythmic way, with 2 seconds of glide distraction and then a 2-second break. Each technique was done for 2 minutes \[36\]. Posterior gliding was performed by maintaining lateral humeral distraction with the glenohumeral in abduction range and the scapula stabilized. Then the therapist applied posterior glide in an oscillating manner. For inferior gliding, with the scapula stabilized, the therapist maintained lateral humeral distraction while applying inferior glide in the resting position of the glenohumeral joint. Patients had 3 sessions of joint mobilization per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Description: Patients were in supine lying position during the whole treatment. The techniques were performed in a rhythmic way, with 2 seconds of glide distraction and then a 2-second break. Each technique was done for 2 minutes \[36\]. Posterior gliding was performed by maintaining lateral humeral distraction with the glenohumeral in abduction range and the scapula stabilized. Then the therapist applied posterior glide in an oscillating manner. For inferior gliding, with the scapula stabilized, the therapist maintained lateral humeral distraction while applying inferior glide in the resting position of the glenohumeral joint. Patients had 3 sessions of joint mobilization per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Description: Patients also in this group remained in supine lying position. Median nerve mobilization was performed by placing the scapula in a depressed position with one hand while placing the elbow in 90° flexion, forearm in supination, and wrist and fingers in extension with the other hand. Then, the therapist passively abducted the shoulder into 90- 100° and available external rotation ROM of the arm. Then from this position, the therapist extended the elbow with or without contra lateral side bending of the neck (tensioner or slider technique, respectively). Patients performed 30 repetitions of slider median nerve mobilization by performing elbow extension and wrist extension, with the neck placed in ipsilateral side bending or performing elbow flexion and wrist flexion with the neck placed in contralateral side bending. \[35\]. Tensioner technique was performed by applying simultaneous elbow extension with contralateral side bending of the neck and hold for 15 sec and relax for 10 sec .
Study: NCT06663982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft + L-PRF
Description: After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket. Following papilla incisions, an intra-sulcular incision on the vestibular side of the extraction socket will be extended with a #15c scalpel, creating a socket to insert the connective tissue graft (CTG). The CTG will be harvested from the palatal area following a specific incision technique to obtain a graft around 1.5 mm thick, which will be fixed with a mattress suture.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF
Description: After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days.
Study: NCT06663696

Intervention type: DEVICE
Intervention: Supraflex Cruz Sirolimus-eluting Coronary Stent System
Description: Biodegradable polymer-coated, cobalt-chromium sirolimus-eluting coronary stent
Study: NCT06663007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48
Description: During the patient treatment phase, the subjects received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks until disease progression or death occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48
Description: During the patient treatment phase, the subjects received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks until disease progression or death occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: During the treatment phase of the patient, the subjects received subcutaneous injections of Envafolimab (400 mg) every 3 weeks until the patient experienced disease progression or death.
Study: NCT06014658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibody-Drug Conjugate
Description: MBRC-101: AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibody-Drug Conjugate
Description: MBRC-101: AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE